Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
An announcement from Medley ( (JP:4480) ) is now available.
Medley reported consolidated net sales of ¥36.79 billion for the fiscal year ended Dec. 31, 2025, up 25.5% year on year, while EBITDA rose 17.2%, but operating profit fell 7.6% and profit attributable to owners of parent dropped 65.1% amid a sharp decline in ordinary profit. Total assets shrank to ¥41.25 billion and the equity ratio slid to 35.9%, reflecting heavier cash outflows from investing and financing activities, though the company ended the year with ¥8.58 billion in cash and cash equivalents and again paid no dividends.
The company expects a rebound in profitability in 2026, forecasting a 26.1% rise in net sales to ¥46.4 billion and an 84.5% jump in profit attributable to owners of parent to ¥1.8 billion, with a stronger operating margin. Medley also streamlined its consolidation scope by deconsolidating three subsidiaries, a move that could sharpen its strategic focus, while maintaining a zero‑dividend policy to prioritize reinvestment and balance sheet management.
The most recent analyst rating on (JP:4480) stock is a Hold with a Yen2772.00 price target. To see the full list of analyst forecasts on Medley stock, see the JP:4480 Stock Forecast page.
More about Medley
Medley, Inc. is a Tokyo Stock Exchange‑listed company operating under Japanese GAAP, focused on digital healthcare and medical‑related services in Japan. The company generates revenue through online platforms and solutions for the medical sector, positioning itself as a growth‑oriented player in the healthcare technology and services industry.
Average Trading Volume: 293,557
Technical Sentiment Signal: Sell
Current Market Cap: Yen78.17B
For a thorough assessment of 4480 stock, go to TipRanks’ Stock Analysis page.